Natural killer cell activity as a biomarker for the diagnosis of lung cancer in high-risk patients

被引:3
作者
Borg, Morten [1 ,2 ,3 ]
Wen, Sara Witting Christensen [4 ,5 ]
Hansen, Torben Frostrup [4 ,5 ]
Jakobsen, Anders [4 ,5 ]
Andersen, Rikke Fredslund [6 ]
Hilberg, Ole [3 ,5 ]
Weinreich, Ulla Moller [1 ,2 ]
Nederby, Line [6 ]
机构
[1] Aalborg Univ Hosp, Dept Resp Dis, Aalborg, Denmark
[2] Aalborg Univ, Dept Clin Med, Aalborg, Denmark
[3] Univ Hosp Southern Denmark, Lillebaelt Hosp Vejle, Dept Internal Med, Vejle, Denmark
[4] Univ Hosp Southern Denmark, Lillebaelt Hosp Vejle, Dept Oncol, Vejle, Denmark
[5] Univ Southern Denmark, Inst Reg Hlth Res, Odense, Denmark
[6] Univ Hosp Southern Denmark, Lillebaelt Hosp Vejle, Dept Clin Biochem, Vejle, Denmark
关键词
Natural killer cell; lung cancer; interferon gamma; screening; biomarker; high-risk; PROSTATE-CANCER; STAGE; ASSOCIATION;
D O I
10.1177/03000605221108924
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objective Natural killer (NK) cells play an essential role in the immune response against cancer. However, immune escape mechanisms may cause inferior NK cell activity (NKA) in patients with cancer. This prospective study examined the relationship between NKA and lung cancer in a high-risk cohort. Methods In a cohort study, 250 participants referred by their general practitioner for suspicion of lung cancer were included. Before clinical investigation, blood was collected into NK Vue tubes, and the level of interferon gamma after 24 hours served as a surrogate marker for NKA. Results Among 250 patients, 79 were diagnosed with lung cancer. No difference in NKA was found between patients with lung cancer and control participants in which lung cancer was ruled out (median 226 pg/mL vs. 450 pg/mL). However, there was a significant difference in NKA between patients with late-stage lung cancer and controls (median 161 pg/mL vs. 450 pg/mL). A linear regression model showed that NKA was not influenced by age, sex or smoking status. Conclusions The significantly lower NKA in patients with late-stage lung cancer warrants further investigation combining NKA with other biomarkers and examining the potential role of NKA as a marker of disseminated disease.
引用
收藏
页数:10
相关论文
共 32 条
[1]   Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity [J].
Alspach, Elise ;
Lussier, Danielle M. ;
Schreiber, Robert D. .
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY, 2019, 11 (03)
[2]  
Barkin J, 2017, CAN J UROL, V24, P8708
[3]   Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy? [J].
Ben-Shmuel, Aviad ;
Biber, Guy ;
Barda-Saad, Mira .
FRONTIERS IN IMMUNOLOGY, 2020, 11
[4]   Performance of the EarlyCDT® Lung test in detection of lung cancer and pulmonary metastases in a high-risk cohort [J].
Borg, Morten ;
Wen, Sara W. C. ;
Nederby, Line ;
Hansen, Torben Frostrup ;
Jakobsen, Anders ;
Andersen, Rikke Fredslund ;
Weinreich, Ulla Moller ;
Hilberg, Ole .
LUNG CANCER, 2021, 158 :85-90
[5]   Next-generation sequencing in liquid biopsy: cancer screening and early detection [J].
Chen, Ming ;
Zhao, Hongyu .
HUMAN GENOMICS, 2019, 13 (1) :34
[6]   Natural killer cells and other innate lymphoid cells in cancer [J].
Chiossone, Laura ;
Dumas, Pierre-Yves ;
Vienne, Margaux ;
Vivier, Eric .
NATURE REVIEWS IMMUNOLOGY, 2018, 18 (11) :671-688
[7]   Efficacy of natural killer cell activity as a biomarker for predicting immunotherapy response in non-small cell lung cancer [J].
Choi, Myeong Geun ;
Kim, Yeon Joo ;
Lee, Jae Cheol ;
Rho, Jin Kyung ;
Choi, Chang-Min .
THORACIC CANCER, 2020, 11 (11) :3337-3345
[8]   Clinical utility of a novel natural killer cell activity assay for diagnosing non-small cell lung cancer: a prospective pilot study [J].
Choi, Sue In ;
Lee, Seung Hyeun ;
Park, Ji-Young ;
Kim, Kyoung-Ah ;
Lee, Eun Joo ;
Lee, Sang Yeub ;
In, Kwang Ho .
ONCOTARGETS AND THERAPY, 2019, 12 :1661-1669
[9]   The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer [J].
Goldstraw, Peter ;
Chansky, Kari ;
Crowley, John ;
Rami-Porta, Ramon ;
Asamura, Hisao ;
Eberhardt, Wilfried E. E. ;
Nicholson, Andrew G. ;
Groome, Patti ;
Mitchell, Alan ;
Bolejack, Vanessa .
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (01) :39-51
[10]   Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins [J].
Guida, Florence ;
Sun, Nan ;
Bantis, Leonidas E. ;
Muller, David C. ;
Li, Peng ;
Taguchi, Ayumu ;
Dhillon, Dilsher ;
Kundnani, Deepali L. ;
Patel, Nikul J. ;
Yan, Qingxiang ;
Byrnes, Graham ;
Moons, Karel G. M. ;
Tjonneland, Anne ;
Panico, Salvatore ;
Agnoli, Claudia ;
Vineis, Paolo ;
Palli, Domenico ;
Bueno-de-Mesquita, Bas ;
Peeters, Petra H. ;
Agudo, Antonio ;
Huerta, Jose M. ;
Dorronsoro, Miren ;
Rodriguez Barranco, Miguel ;
Ardanaz, Eva ;
Travis, Ruth C. ;
Byme, Karl Smith ;
Boeing, Heiner ;
Steffen, Annika ;
Kaaks, Rudolf ;
Huesing, Anika ;
Trichopoulou, Antonia ;
Lagiou, Pagona ;
La Vecchia, Carlo ;
Severi, Gianluca ;
Boutron-Ruault, Marie-Christine ;
Sandanger, Torkjel M. ;
Weiderpass, Elisabete ;
Nost, Therese H. ;
Tsilidis, Kostas ;
Riboli, Elio ;
Grankvist, Kjell ;
Johansson, Mikael ;
Goodman, Gary E. ;
Feng, Ziding ;
Brennan, Paul ;
Johansson, Mattias ;
Hanash, Samir M. .
JAMA ONCOLOGY, 2018, 4 (10)